The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Future directions in the management of frail patients with myeloma
Kenneth Shain, MD, PhD, Moffitt Cancer Center, Tampa, FL, discusses unmet needs and future directions in the management of frail patients with multiple myeloma (MM). Dr Shain emphasizes the need to improve biomarkers to allow for better identification of frail patients, enabling clinicians to adapt therapy to a patient’s individual needs. He also highlights the importance of translating knowledge about treating this patient population into the community setting to ensure that physicians are aware of the best approaches to use in clinical practice. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The key is for all of us to recognize what that really is. And again, one of the things we all talk about, I think, very well, and maybe practice not so well, is what is a frail patient? And we have lots of scoring systems. We have lots of things that you can go down. We have tests you can do, but we knew we need to do a better job of trying to figure out how to make that clinically feasible versus just using clinicians as the guide...
The key is for all of us to recognize what that really is. And again, one of the things we all talk about, I think, very well, and maybe practice not so well, is what is a frail patient? And we have lots of scoring systems. We have lots of things that you can go down. We have tests you can do, but we knew we need to do a better job of trying to figure out how to make that clinically feasible versus just using clinicians as the guide. And so finding ways to do that is going to be a really important step. And I’m hoping that we can develop better biomarkers of what that really looks like, whether it be sarcopenia from imaging, whether it be lab tests we can get, and physicians can see this right away. These are things that can be the next step to helping deal with the frailty of patients because really we need to adapt the therapy to the patient. Like, you know, there’s frail frail, what we talked about, like, you know, single drug, maybe adding things if necessary. But most patients can handle multiple agents, but again they don’t need to handle them at the full dose.
These are all things that we really need to recognize and make sure are translated to the community where people are getting most of the therapy. Just because we say, you know, triplet therapy, DRd for most patients that are transplant ineligible, quote unquote, or now even quads for folks that are more fit on that level, that doesn’t mean they need the full dose of any of these agents. They need to make sure that it’s truly adjusted for the patient in front of them, and making sure they get on therapy is the most important thing. So tools to help us do that a little better, I think, is going to be a really critical next step for where we’re going with treating our frail patients. Because they do need these therapies, they do need therapy, but they need therapy to be given in a very respectful and responsible way.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Sanofi: Consultancy; BMS: Consultancy, Research Funding; Glaxo Smith Kline: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Takeda: Consultancy; Karyopharm: Research Funding; Janssen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Research Funding; Adaptive Biotech: Consultancy; Amgen: Research Funding; Karyopharm, Janssen, Adaptive Biotechnologies, GlaxoSmithKline, BMS, Sanofi, Regeneron: Honoraria.
